Ribociclib
A CDK4/6 inhibitor used in combination with hormone therapy to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in women. It works by blocking proteins that drive cancer cell division, helping to slow tumor growth.
Molecular Weight
434.5000 g/mol
LogP
2.20
TPSA
91.20 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.
2D Structure
Cite this structure
Embed this structure
SMILES
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1
InChI
InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)
Molecular Formula
C23H30N8O
HBD / HBA
2 / 7
Rotatable Bonds
5
Heavy Atoms
32
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
A CDK4/6 inhibitor used in combination with hormone therapy to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in women. It works by blocking proteins that drive cancer cell division, helping to slow tumor growth.
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.
Yes, Ribociclib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3545110. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 44631912. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ribociclib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ribociclib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ribociclib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ribociclib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ribociclib"></drugfyi-drug>